Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 11, 2010, Pages 4910-4913

  Lambert Niclot, Sidonie ^a   Peytavin, Gilles ^b   Duvivier, Claudine ^c,d   Poirot, Catherine ^a   Algarte Genin, Michèle ^e   Pakianather, Sophie ^e   Meynard, Jean Luc ^f   Valantin, Marc Antoine ^a   Molina, Jean Michel ^g   Flandre, Philippe ^a,e   Katlama, Christine ^a   Calvez, Vincent ^a   Marcelin, Anne Geneviève ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b BICHAT HOSPITAL   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d INSTITUT PASTEUR   (France)

^e INSERM   (France)

^f HÔPITAL SAINT ANTOINE   (France)

^g SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EMTRICITABINE; LAMIVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG PROTEIN BINDING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIPOPHILICITY; MALE; MASS SPECTROMETRY; MONOTHERAPY; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; SEMINAL PLASMA; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VIRUS LOAD; VIRUS SHEDDING;

DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PLASMA; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; SEMEN; SULFONAMIDES;

EID: 78049301627     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00725-10     Document Type: Article

References (21)

1. Bland, J. M., and D. G. Altman. 1986. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet i:307-310.
2. Bujan, L., M. Daudin, T. Matsuda, L. Righi, L. Thauvin, L. Berges, J. Izopet, A. Berrebi, P. Massip, and C. Pasquier. 2004. Factors of intermittent HIV-1 excretion in semen and efficiency of sperm processing in obtaining spermatozoa without HIV-1 genomes. AIDS 18:757-766.
3. Chambers, E., D. M. Wagrowski-Diehl, Z. Lu, and J. R. Mazzeo. 2007. Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 852:22-34.
4. Cohen, M. S., C. Gay, A. D. Kashuba, S. Blower, and L. Paxton. 2007. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann. Intern. Med. 146:591-601.
5. De Meyer, S., H. Azijn, D. Surleraux, D. Jochmans, A. Tahri, R. Pauwels, P. Wigerinck, and M. P. de Bethune. 2005. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob. Agents Chemother. 49:2314-2321.
6. Ghosn, J., M. L. Chaix, G. Peytavin, J. L. Bresson, J. Galimand, P. M. Girard, F. Raffi, I. Cohen-Codar, J. F. Delfraissy, and C. Rouzioux. 2008. Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine. J. Antimicrob. Chemother. 61:1344-1347.
7. Ghosn, J., M. L. Chaix, G. Peytavin, E. Rey, J. L. Bresson, C. Goujard, C. Katlama, J. P. Viard, J. M. Treluyer, and C. Rouzioux. 2004. Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS 18:1958-1961.
8. Gupta, P., C. Leroux, B. K. Patterson, L. Kingsley, C. Rinaldo, M. Ding, Y. Chen, K. Kulka, W. Buchanan, B. McKeon, and R. Montelaro. 2000. Human immunodeficiency virus type 1 shedding pattern in semen correlates with the compartmentalization of viral quasispecies between blood and semen. J. Infect. Dis. 182:79-87.
9. Gutmann, C., M. Opravil, C. Fux, H. J. Furrer, L. A. Decosterd, M. Cavassini, S. Yerly, B. Hirschel, P. Vernazza, and the Swiss HIV Cohort Study. 2009. Abstr. Deutsch Österreichisch Schweizerische AIDS Kongr. (SÖDAK), St Gallen, Switzerland, 24 to 27 June 2009, abstr. P421.
10. Jung, B. H., N. L. Rezk, A. S. Bridges, A. H. Corbett, and A. D. Kashuba. 2007. Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. Biomed. Chromatogr. 21:1095-1104.
11. Katlama, C., R. Esposito, J. M. Gatell, J. C. Goffard, B. Grinsztejn, A. Pozniak, J. Rockstroh, A. Stoehr, N. Vetter, P. Yeni, W. Parys, and T. Vangeneugden. 2007. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 21:395-402.
12. Katlama, C., M. A. Valantin, M. Algarte-Genin, C. Duvivier, S. Lambert-Niclot, P. M. Girard, J. M. Molina, B. Hosten, S. Pakianather, G. Peytavin, A. G. Marcelin, and P. Flandre. 2009. Abstr. 5th IAS Conf. HIV Pathol. Treat. Prevent., Cape Town, South Africa, 19 to 22 June, abstr. WELBB102.
13. Marcelin, A. G., R. Tubiana, S. Lambert-Niclot, G. Lefebvre, S. Dominguez, M. Bonmarchand, D. Vauthier-Brouzes, F. Marguet, N. Mousset-Simeon, G. Peytavin, and C. Poirot. 2008. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma. AIDS 22:1677-1679.
14. Molina, J. M., and A. Hill. 2007. Darunavir (TMC114): a new HIV-1 protease inhibitor. Expert Opin. Pharmacother. 8:1951-1964.
15. Ortiz, R., E. Dejesus, H. Khanlou, E. Voronin, J. van Lunzen, J. Andrade-Villanueva, J. Fourie, S. De Meyer, M. De Pauw, E. Lefebvre, T. Vangeneugden, and S. Spinosa-Guzman. 2008. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 22:1389-1397.
16. Pasquier, C., D. Anderson, C. Andreutti-Zaugg, R. Baume-Berkenbosch, F. Damond, A. Devaux, Y. Englert, J. Galimand, C. Gilling-Smith, O. Guist'hau, L. Hollander, M. Leruez-Ville, B. Lesage, A. Maillard, A. G. Marcelin, M. P. Schmitt, A. Semprini, M. Vourliotis, C. Xu, and L. Bujan. 2006. Multicenter quality control of the detection of HIV-1 genome in semen before medically assisted procreation. J. Med. Virol. 78:877-882.
17. Pasquier, C., K. Saune, S. Raymond, N. Moinard, M. Daudin, L. Bujan, and J. Izopet. 2009. Determining seminal plasma human immunodeficiency virus type 1 load in the context of efficient highly active antiretroviral therapy. J. Clin. Microbiol. 47:2883-2887.
18. Sadler, B. M., C. D. Hanson, G. E. Chittick, W. T. Symonds, and N. S. Roskell. 1999. Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults. Antimicrob. Agents Chemother. 43:1686-1692.
19. Taylor, S., A. Jayasuriya, N. Dufty, G. Gilleran, A. Berry, D. Back, and E. Smit. 2010. Abstr. 17th Conf. Retrovir. Opport. Infect., San Fransisco, CA, 16 to 19 February 2010, abstr. 611.
20. Taylor, S., and A. S. Pereira. 2001. Antiretroviral drug concentrations in semen of HIV-1 infected men. Sex. Transm. Infect. 77:4-11.
21. Vermeir, M., S. Lachau-Durand, G. Mannens, F. Cuyckens, B. van Hoof, and A. Raoof. 2009. Absorption, metabolism, and excretion of darunavir, a new protease inhibitor, administered alone and with low-dose ritonavir in healthy subjects. Drug Metab. Dispos. 37:809-820.